カテゴリ： Allied Market Research, 世界, 医療/バイオ

ペプチド治療薬のグローバル市場（2021〜2031）：代謝、腫瘍、胃腸、神経、心血管、その他

■ 英語タイトル：Peptide Therapeutics Market By Application (Metabolic, Oncology, Gastrointestinal, Neurological, Cardiovascular, Others), By Route of administration (Oral, Parenteral), By Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
	■ 発行会社/調査会社：Allied Market Research ■ 商品コード：ALD23FB212 ■ 発行日：2022年10月 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：309 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

■ 販売価格オプション（消費税別）

Online Only（1名閲覧、印刷不可）	USD3,570 ⇒換算￥542,640	見積依頼/購入/質問フォーム
Single User（1名閲覧）	USD5,730 ⇒換算￥870,960	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）	USD9,600 ⇒換算￥1,459,200	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ペプチド治療薬のグローバル市場（2021〜2031）：代謝、腫瘍、胃腸、神経、心血管、その他]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に33,257.72百万ドルであった世界のペプチド治療薬市場規模が、2031年までに64,336.12百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）6.8%で成長すると予測しています。本レポートは、ペプチド治療薬の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、用途別（代謝、腫瘍、胃腸、神経、その他）分析、投与経路別（経口、非経口）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Eli Lilly and Company、Amgen Inc.、Pfizer Inc.、Takeda Pharmaceutical Company Limited、Novo Nordisk A/S、Sanofi SA、Ever Neuro Pharma GmbH、Baush Health、GlaxoSmithKline plc、Abbvie (Allergan)などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のペプチド治療薬市場規模：用途別
- 代謝における市場規模
- 腫瘍における市場規模
- 胃腸における市場規模
- 神経における市場規模
- その他における市場規模
・世界のペプチド治療薬市場規模：投与経路別
- 経口投与における市場規模
- 非経口投与における市場規模
・世界のペプチド治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のペプチド治療薬市場規模：地域別
- 北米のペプチド治療薬市場規模
- ヨーロッパのペプチド治療薬市場規模
- アジア太平洋のペプチド治療薬市場規模
- 中南米・中東・アフリカのペプチド治療薬市場規模
・企業状況
・企業情報

世界のペプチド治療薬市場は、2021年に332億5,772万ドル、2031年には643億3,612万ドルに達すると推定され、2022年から2031年までの年平均成長率は6.8%となる見込みです。

ペプチドとは、アミノ酸が化学的に結合した小さな鎖のことで、通常は2～50個のアミノ酸が結合しています（ペプチド結合と呼ばれます）。ペプチドはタンパク質よりも小さく、約2～50個のアミノ酸で構成されています。病気の治療に使われるペプチドはペプチド治療として知られています。ペプチド治療は、天然に存在するペプチドがホルモン、成長因子、イオンチャネルのリガンド、抗作用として果たすことができるような役割を再現します。ペプチドは体内で代謝されることから、ペプチド治療薬は一般的に安全で忍容性が高いと考えられています。ペプチド治療薬市場の成長を促進する主な要因は、糖尿病やがんなどの慢性疾患の発生率の上昇、ペプチド治療薬の大幅な開発、ペプチド治療薬のR&Dの成長などが挙げられます。加えて、主要企業によるR&Dの急増は、市場の主要な傾向であり、予測期間における成長を促進すると予想されます。
慢性疾患の有病率の上昇がペプチド治療薬市場を牽引するとみられています。例えば、米国国立生物工学情報センター（NCBI）によると、消化器疾患はアメリカで年間6000万人から7000万人が罹患していると推定され、大腸がんはアメリカ人男女の間で診断されるがんの第2位となっています。このように、世界的に慢性疾患の有病率が増加しており、これがペプチド治療薬の必要性をさらに浮き彫りにし、市場の成長を引き起こしています。
しかし、ペプチドの生物学的利用能の低さや薬剤開発に伴う高コストが市場の成長を妨げると予想されます。逆に、消費者の需要を満たす新興市場の成長機会は、投資家にとって市場に投資する絶好の機会となることが期待されます。

世界のペプチド治療薬市場は、用途、投与経路、流通チャネル、地域に基づいて区分されます。用途別では、代謝、腫瘍、消化器、神経、心血管、その他に分類されます。投与経路別では、経口剤と非経口剤に分類されます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンライン薬局に分類されます。病院薬局セグメントはさらに私立と公立に二分されます。地域別では、北米、欧州、アジア太平洋、中南米、中東、アフリカ（LAMEA）に市場を分けて分析しています。

本レポートに掲載されている主要企業は、AbbVie Inc.、Amgen Inc.、Bausch Health Companies Inc.、Eli Lilly and company、Ever Neuro Pharma GmbH、GalaxoSmithKline plc、Novo Nordisk、Pfizer Inc.、Sanofi-GSK、武田薬品工業株式会社です。

〈ステークホルダーにとっての主なメリット〉
・当レポートは、2021年から2031年までのペプチド治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、ペプチド治療薬市場の有力な機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・ペプチド治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界のペプチド治療薬市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
用途別
代謝
腫瘍
消化器
神経
循環器
その他

投与経路別
経口
非経口

流通チャネル別
病院薬局
ドラッグストア・小売薬局
オンライン薬局

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Eli Lilly and Company
Amgen Inc.
Pfizer Inc.
武田薬品工業株式会社
Novo Nordisk A/S
Sanofi SA
Ever Neuro Pharma GmbH
Baush Health
GlaxoSmithKline plc
Abbvie ( Allergan)

*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: PEPTIDE THERAPEUTICS MARKET, BY APPLICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Metabolic
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oncology
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Gastrointestinal
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Neurological
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Cardiovascular
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Others
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
CHAPTER 5: PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Parenteral
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Hospital pharmacies Peptide Therapeutics Market by Hospital type
6.2.4.1 Private Market size and forecast, by region
6.2.4.2 Public Market size and forecast, by region
6.3 Drug store and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: PEPTIDE THERAPEUTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Application
7.2.3 North America Market size and forecast, by Route of administration
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.4.1 North America Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Application
7.2.5.1.2 Market size and forecast, by Route of administration
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Application
7.2.5.2.2 Market size and forecast, by Route of administration
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Application
7.2.5.3.2 Market size and forecast, by Route of administration
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Application
7.3.3 Europe Market size and forecast, by Route of administration
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.4.1 Europe Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Application
7.3.5.1.2 Market size and forecast, by Route of administration
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Application
7.3.5.2.2 Market size and forecast, by Route of administration
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Application
7.3.5.3.2 Market size and forecast, by Route of administration
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Application
7.3.5.4.2 Market size and forecast, by Route of administration
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Application
7.3.5.5.2 Market size and forecast, by Route of administration
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Application
7.3.5.6.2 Market size and forecast, by Route of administration
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Application
7.4.3 Asia-Pacific Market size and forecast, by Route of administration
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.4.1 Asia-Pacific Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Application
7.4.5.1.2 Market size and forecast, by Route of administration
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Application
7.4.5.2.2 Market size and forecast, by Route of administration
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Application
7.4.5.3.2 Market size and forecast, by Route of administration
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Application
7.4.5.4.2 Market size and forecast, by Route of administration
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Application
7.4.5.5.2 Market size and forecast, by Route of administration
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Application
7.4.5.6.2 Market size and forecast, by Route of administration
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Application
7.5.3 LAMEA Market size and forecast, by Route of administration
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.4.1 LAMEA Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Application
7.5.5.1.2 Market size and forecast, by Route of administration
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Application
7.5.5.2.2 Market size and forecast, by Route of administration
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Application
7.5.5.3.2 Market size and forecast, by Route of administration
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Application
7.5.5.4.2 Market size and forecast, by Route of administration
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Eli Lilly and Company
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Amgen Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Pfizer Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Takeda Pharmaceutical Company Limited
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novo Nordisk A/S
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Sanofi SA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Ever Neuro Pharma GmbH
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Baush Health
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 GlaxoSmithKline plc
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Abbvie ( Allergan)
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 2. PEPTIDE THERAPEUTICS MARKET, FOR METABOLIC, BY REGION, 2021-2031 ($MILLION)
TABLE 3. PEPTIDE THERAPEUTICS MARKET FOR METABOLIC, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. PEPTIDE THERAPEUTICS MARKET, FOR ONCOLOGY, BY REGION, 2021-2031 ($MILLION)
TABLE 5. PEPTIDE THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. PEPTIDE THERAPEUTICS MARKET, FOR GASTROINTESTINAL, BY REGION, 2021-2031 ($MILLION)
TABLE 7. PEPTIDE THERAPEUTICS MARKET FOR GASTROINTESTINAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. PEPTIDE THERAPEUTICS MARKET, FOR NEUROLOGICAL, BY REGION, 2021-2031 ($MILLION)
TABLE 9. PEPTIDE THERAPEUTICS MARKET FOR NEUROLOGICAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. PEPTIDE THERAPEUTICS MARKET, FOR CARDIOVASCULAR, BY REGION, 2021-2031 ($MILLION)
TABLE 11. PEPTIDE THERAPEUTICS MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. PEPTIDE THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. PEPTIDE THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 15. PEPTIDE THERAPEUTICS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 16. PEPTIDE THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. PEPTIDE THERAPEUTICS MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
TABLE 18. PEPTIDE THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. PEPTIDE THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 21. PEPTIDE THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. GLOBAL HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)
TABLE 23. PEPTIDE THERAPEUTICS MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION)
TABLE 24. PEPTIDE THERAPEUTICS MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION)
TABLE 25. PEPTIDE THERAPEUTICS MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 26. PEPTIDE THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. PEPTIDE THERAPEUTICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 28. PEPTIDE THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. PEPTIDE THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 36. U.S. PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 37. U.S. PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. CANADA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 39. CANADA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 40. CANADA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 42. MEXICO PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 43. MEXICO PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 45. EUROPE PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 46. EUROPE PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. EUROPE HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. GERMANY PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 50. GERMANY PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 51. GERMANY PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. FRANCE PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 53. FRANCE PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 54. FRANCE PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. UK PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 56. UK PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 57. UK PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. ITALY PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 59. ITALY PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 60. ITALY PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. SPAIN PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 62. SPAIN PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 63. SPAIN PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 66. REST OF EUROPE PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 72. JAPAN PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 73. JAPAN PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 74. JAPAN PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. CHINA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 76. CHINA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 77. CHINA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. INDIA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 79. INDIA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 80. INDIA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. AUSTRALIA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 82. AUSTRALIA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 83. AUSTRALIA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 91. LAMEA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 92. LAMEA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. LAMEA HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)
TABLE 94. LAMEA PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 95. BRAZIL PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 96. BRAZIL PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 97. BRAZIL PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 107.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 108.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 109.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 110.ELI LILLY AND COMPANY: NET SALES,
TABLE 111.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 112.AMGEN INC.: COMPANY SNAPSHOT
TABLE 113.AMGEN INC.: OPERATING SEGMENTS
TABLE 114.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 115.AMGEN INC.: NET SALES,
TABLE 116.AMGEN INC.: KEY STRATERGIES
TABLE 117.PFIZER INC.: COMPANY SNAPSHOT
TABLE 118.PFIZER INC.: OPERATING SEGMENTS
TABLE 119.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 120.PFIZER INC.: NET SALES,
TABLE 121.PFIZER INC.: KEY STRATERGIES
TABLE 122.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 123.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
TABLE 124.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 125.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
TABLE 126.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
TABLE 127.NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 128.NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 129.NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 130.NOVO NORDISK A/S: NET SALES,
TABLE 131.NOVO NORDISK A/S: KEY STRATERGIES
TABLE 132.SANOFI SA: COMPANY SNAPSHOT
TABLE 133.SANOFI SA: OPERATING SEGMENTS
TABLE 134.SANOFI SA: PRODUCT PORTFOLIO
TABLE 135.SANOFI SA: NET SALES,
TABLE 136.SANOFI SA: KEY STRATERGIES
TABLE 137.EVER NEURO PHARMA GMBH: COMPANY SNAPSHOT
TABLE 138.EVER NEURO PHARMA GMBH: OPERATING SEGMENTS
TABLE 139.EVER NEURO PHARMA GMBH: PRODUCT PORTFOLIO
TABLE 140.EVER NEURO PHARMA GMBH: NET SALES,
TABLE 141.EVER NEURO PHARMA GMBH: KEY STRATERGIES
TABLE 142.BAUSH HEALTH: COMPANY SNAPSHOT
TABLE 143.BAUSH HEALTH: OPERATING SEGMENTS
TABLE 144.BAUSH HEALTH: PRODUCT PORTFOLIO
TABLE 145.BAUSH HEALTH: NET SALES,
TABLE 146.BAUSH HEALTH: KEY STRATERGIES
TABLE 147.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 148.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 149.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 150.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 151.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 152.ABBVIE ( ALLERGAN): COMPANY SNAPSHOT
TABLE 153.ABBVIE ( ALLERGAN): OPERATING SEGMENTS
TABLE 154.ABBVIE ( ALLERGAN): PRODUCT PORTFOLIO
TABLE 155.ABBVIE ( ALLERGAN): NET SALES,
TABLE 156.ABBVIE ( ALLERGAN): KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

ペプチド治療薬のグローバル市場（2021〜2031）：代謝、腫瘍、胃腸、神経、心血管、その他

グローバル市場調査会社